Skip to main
FHTX
FHTX logo

Foghorn Therapeutics (FHTX) Stock Forecast & Price Target

Foghorn Therapeutics (FHTX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Foghorn Therapeutics Inc is advancing its proprietary Gene Traffic Control platform, which enables comprehensive insights into the chromatin regulatory system, positioning the company for potential breakthroughs in targeting genetically determined dependencies. The ongoing clinical development of FHD-286 and FHD-909 showcases the company's innovative approach, particularly with FHD-909 demonstrating best-in-class potential for selective SMARCA2 inhibition in SMARCA4-deficient cancers, which may lead to improved efficacy over existing treatments. Positive data expected by late 2026 could serve as a significant milestone, indicating robust prospects for Foghorn Therapeutics's product pipeline and overall growth.

Bears say

Foghorn Therapeutics faces considerable challenges that contribute to a negative outlook on its stock, primarily due to its reliance on the uncertain timelines for regulatory approval of its drug candidates. The company operates in a highly competitive biotechnology sector dominated by larger firms with more substantial resources, which raises concerns about its ability to successfully develop and market its therapeutics. Additionally, anticipated future equity financing needs could lead to dilution for existing shareholders, further compounding financial risks associated with the company's capital structure.

Foghorn Therapeutics (FHTX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Foghorn Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Foghorn Therapeutics (FHTX) Forecast

Analysts have given Foghorn Therapeutics (FHTX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Foghorn Therapeutics (FHTX) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Foghorn Therapeutics (FHTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.